Literature DB >> 21874319

A mathematical model of calcium and phosphorus metabolism in two forms of hyperparathyroidism.

J F Raposo1, A Pires, H Yokota, H G Ferreira.   

Abstract

Parathyroid hormone (PTH) plays a critical role in calcium and phosphorus metabolism. Interestingly, in two forms of hyperparathyroidism (excessive amount of PTH in the serum), the metabolic disturbances in patients with chronic kidney disease (CKD) significantly differ from those with primary hyperparathyroidism (PHP). Since an intuitive understanding of these PTH-linked regulatory mechanisms are hardly possible, we developed a mathematical model using clinical data (1586 CKD and 40 PHP patients). The model was composed of a set of ordinary differential equations, in which the regulatory mechanism of PTH together with other key factors such as 1,25-Dihydroxyvitamin D (1,25(OH)₂D) and calcium was described in the tissues including bone, the kidney, the serum, and the parathyroid glands. In this model, an increase in PTH was induced by its autonomous production in PHP, while PTH in CKD was elevated by a decrease in feedback inhibition of 1,25(OH)₂D in the serum, as well as an increase in stimulation by phosphorus in the serum. The model-based analysis revealed characteristic differences in the outcomes of hyperparathyroidism in CKD and PHP. The calcium exchange in bone, for instance, was predicted significantly higher in PHP than CKD. Furthermore, we evaluated the observed and predicted responses to the administration of calcimimetics, a recently developed synthetic drug that modulated efficacy of calcium-sensing receptors. The results herein support the notion that the described model would enable us to pose testable hypotheses about the actions of PTH, providing a quantitative analytical tool for evaluating treatment strategies of PHP and CKD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874319     DOI: 10.1007/s12020-011-9521-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

Review 1.  Parathyroid hormone and periosteal bone expansion.

Authors:  A Michael Parfitt
Journal:  J Bone Miner Res       Date:  2002-10       Impact factor: 6.741

Review 2.  Misconceptions (3): calcium leaves bone only by resorption and enters only by formation.

Authors:  A M Parfitt
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

3.  Modeling the interactions between osteoblast and osteoclast activities in bone remodeling.

Authors:  Vincent Lemaire; Frank L Tobin; Larry D Greller; Carolyn R Cho; Larry J Suva
Journal:  J Theor Biol       Date:  2004-08-07       Impact factor: 2.691

4.  Inferring disease mechanisms from epidemiological data in chronic kidney disease: calcium and phosphorus metabolism.

Authors:  Ana Pires; Teresa Adragão; Maria João Pais; José Vinhas; Hugo Gil Ferreira
Journal:  Nephron Clin Pract       Date:  2009-04-24

5.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

6.  Simplified calculation of body-surface area.

Authors:  R D Mosteller
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

7.  Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery.

Authors:  Q Wang; S Palnitkar; A M Parfitt
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

8.  Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

Authors:  Chaim Charytan; Jack W Coburn; Michel Chonchol; James Herman; Y Howard Lien; Wei Liu; Preston S Klassen; Laura C McCary; Vincent Pichette
Journal:  Am J Kidney Dis       Date:  2005-07       Impact factor: 8.860

9.  Relationships between osteocyte density and bone formation rate in human cancellous bone.

Authors:  S Qiu; D S Rao; S Palnitkar; A M Parfitt
Journal:  Bone       Date:  2002-12       Impact factor: 4.398

10.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  4 in total

1.  The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Authors:  Dan Li; Leping Shao; Haiyan Zhou; Wei Jiang; Wei Zhang; Yan Xu
Journal:  Endocrine       Date:  2012-06-06       Impact factor: 3.633

2.  Evaluation of the 'putative' role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients: intraoperative iPTH assay during parathyroidectomy.

Authors:  G Conzo; A Perna; N Avenia; R M De Santo; C Della Pietra; A Palazzo; A A Sinisi; F Stanzione; L Santini
Journal:  Endocrine       Date:  2012-03-16       Impact factor: 3.633

3.  Transient modulation of calcium and parathyroid hormone stimulates bone formation.

Authors:  Andy B Chen; Kazumasa Minami; João F Raposo; Nariaki Matsuura; Masahiko Koizumi; Hiroki Yokota; Hugo G Ferreira
Journal:  Endocrine       Date:  2016-08-08       Impact factor: 3.633

4.  Novel calcium infusion regimen after parathyroidectomy for renal hyperparathyroidism.

Authors:  Jih Huei Tan; Henry Chor Lip Tan; Seng Cheong Loke; Sarojah A/P Arulanantham
Journal:  Nephrology (Carlton)       Date:  2017-04       Impact factor: 2.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.